NO20024520L - Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer - Google Patents

Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer

Info

Publication number
NO20024520L
NO20024520L NO20024520A NO20024520A NO20024520L NO 20024520 L NO20024520 L NO 20024520L NO 20024520 A NO20024520 A NO 20024520A NO 20024520 A NO20024520 A NO 20024520A NO 20024520 L NO20024520 L NO 20024520L
Authority
NO
Norway
Prior art keywords
side chain
metalloprotease inhibitors
heterocyclic side
substituted
substituted metalloprotease
Prior art date
Application number
NO20024520A
Other languages
English (en)
Other versions
NO20024520D0 (no
Inventor
Stanislaw Pikul
Norman Eugene Ohler
Neil Gregory Almstead
Steven Karl Laughlin
Michael George Natchus
Biswanath De
Original Assignee
Procter & Gamble
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Procter & Gamble filed Critical Procter & Gamble
Publication of NO20024520L publication Critical patent/NO20024520L/no
Publication of NO20024520D0 publication Critical patent/NO20024520D0/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/34—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/60—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D211/62—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4
    • C07D211/66—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals attached in position 4 having a hetero atom as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/04—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C07D309/06—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D309/08—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/14—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)
  • Pyrane Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
NO20024520A 2000-03-21 2002-09-20 Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer NO20024520D0 (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US19130200P 2000-03-21 2000-03-21
PCT/US2001/008931 WO2001070691A1 (en) 2000-03-21 2001-03-02 Heterocyclic side chain containing, n-substituted metalloprotease inhibitors

Publications (2)

Publication Number Publication Date
NO20024520L true NO20024520L (no) 2002-09-20
NO20024520D0 NO20024520D0 (no) 2002-09-20

Family

ID=22704936

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20024520A NO20024520D0 (no) 2000-03-21 2002-09-20 Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer

Country Status (22)

Country Link
US (2) US6949545B2 (no)
EP (1) EP1265864A1 (no)
JP (1) JP2003528080A (no)
KR (1) KR20020081465A (no)
CN (1) CN1425004A (no)
AR (1) AR030197A1 (no)
AU (1) AU2001245891A1 (no)
BR (1) BR0109328A (no)
CA (1) CA2404131A1 (no)
CZ (1) CZ20023145A3 (no)
HU (1) HUP0300235A2 (no)
IL (1) IL151125A0 (no)
MA (1) MA26884A1 (no)
MX (1) MXPA02009311A (no)
NO (1) NO20024520D0 (no)
NZ (1) NZ520657A (no)
PE (1) PE20011137A1 (no)
PL (1) PL365444A1 (no)
RU (1) RU2245876C2 (no)
SK (1) SK12842002A3 (no)
WO (1) WO2001070691A1 (no)
ZA (1) ZA200206298B (no)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4813725B2 (ja) * 1999-12-28 2011-11-09 帝國製薬株式会社 鎮痒用外用剤
WO2001070690A1 (en) * 2000-03-21 2001-09-27 The Procter & Gamble Company Heterocyclic side chain containing metalloprotease inhibitors
EP1373262B1 (en) * 2001-03-14 2010-05-12 Novartis AG Azacycloalkyl substituted acetic acid derivatives for use as mmp inhibitors
US20040213758A1 (en) * 2003-04-23 2004-10-28 Rimon Therapeutics Ltd. Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US20070160655A1 (en) * 2003-04-23 2007-07-12 Sefton Michael V Hydroxyamate-containing materials for the inhibition of matrix metalloproteinases
US7576222B2 (en) 2004-12-28 2009-08-18 Wyeth Alkynyl-containing tryptophan derivative inhibitors of TACE/matrix metalloproteinase
KR100717022B1 (ko) * 2005-08-27 2007-05-10 삼성전자주식회사 잉크젯 프린트헤드 및 그 제조방법
CN101969951B (zh) * 2007-11-16 2012-10-31 雅培制药有限公司 化合物在制备治疗关节炎的药物中的方法
US20100160322A1 (en) 2008-12-04 2010-06-24 Abbott Laboratories Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
UA108193C2 (uk) * 2008-12-04 2015-04-10 Апоптозіндукуючий засіб для лікування раку і імунних і аутоімунних захворювань
US8557983B2 (en) 2008-12-04 2013-10-15 Abbvie Inc. Apoptosis-inducing agents for the treatment of cancer and immune and autoimmune diseases
CN106008322B (zh) * 2008-12-05 2018-09-04 Abbvie 公司 作为用于治疗癌症和免疫疾病的bcl-2-选择性诱发细胞凋亡药剂的磺酰胺衍生物
US8586754B2 (en) 2008-12-05 2013-11-19 Abbvie Inc. BCL-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US8563735B2 (en) 2008-12-05 2013-10-22 Abbvie Inc. Bcl-2-selective apoptosis-inducing agents for the treatment of cancer and immune diseases
US20100319773A1 (en) * 2009-06-22 2010-12-23 Solarmation, Inc. Optics for Concentrated Photovoltaic Cell

Family Cites Families (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4743587A (en) 1985-09-10 1988-05-10 G. D. Searle & Co. Hydroxamic acid based collagenase inhibitors
US4771038A (en) 1986-01-21 1988-09-13 Ici Americas Inc. Hydroxamic acids
DK77487A (da) 1986-03-11 1987-09-12 Hoffmann La Roche Hydroxylaminderivater
ZW23187A1 (en) 1986-12-15 1988-06-29 Hoffmann La Roche Phosphinic acid derivatives
US5183900A (en) 1990-11-21 1993-02-02 Galardy Richard E Matrix metalloprotease inhibitors
US5892112A (en) 1990-11-21 1999-04-06 Glycomed Incorporated Process for preparing synthetic matrix metalloprotease inhibitors
GB9102635D0 (en) 1991-02-07 1991-03-27 British Bio Technology Compounds
GB9107368D0 (en) 1991-04-08 1991-05-22 Smithkline Beecham Plc Novel compounds
WO1992022523A2 (en) 1991-06-14 1992-12-23 Research Corporation Technologies, Inc. Peptide derivatives of collagenase inhibitor
JPH05125029A (ja) 1991-11-06 1993-05-21 Yamanouchi Pharmaceut Co Ltd 新規なアミド化合物又はその塩
CA2126687A1 (en) 1992-01-15 1993-07-22 Charles G. Caldwell Substituted phosphinic acid-containing peptidyl derivatives as antidegenerative agents
AU4267293A (en) 1992-05-01 1993-11-29 British Biotech Pharmaceuticals Limited Use of MMP inhibitors
US5318964A (en) 1992-06-11 1994-06-07 Hoffmann-La Roche Inc. Hydroxamic derivatives and pharmaceutical compositions
AU666727B2 (en) 1992-06-25 1996-02-22 F. Hoffmann-La Roche Ag Hydroxamic acid derivatives
US5326760A (en) 1992-06-29 1994-07-05 Glaxo, Inc. Aminobutanoic acid compounds having metalloprotease inhibiting properties
GB9215665D0 (en) 1992-07-23 1992-09-09 British Bio Technology Compounds
GB9223904D0 (en) 1992-11-13 1993-01-06 British Bio Technology Inhibition of cytokine production
US5646167A (en) 1993-01-06 1997-07-08 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamix acids
US5455258A (en) * 1993-01-06 1995-10-03 Ciba-Geigy Corporation Arylsulfonamido-substituted hydroxamic acids
US5506242A (en) 1993-01-06 1996-04-09 Ciba-Geigy Corporation Arylsufonamido-substituted hydroxamic acids
GB9308695D0 (en) 1993-04-27 1993-06-09 Celltech Ltd Peptidyl derivatives
DE69419473T2 (de) 1993-04-27 2000-03-16 Celltech Therapeutics Ltd. Peptidylderivate als inhibitoren von metalloproteinase
DE69415159T2 (de) 1993-08-02 1999-07-22 Celltech Therapeutics Ltd., Slough, Berkshire Succinamid-derivate, verfahren zu ihrer herstellung und ihre verwendung als gelatinase- und collagenase- inhibitoren
US5545735A (en) 1993-10-04 1996-08-13 Merck & Co., Inc. Benzo-Fused Lactams promote release of growth hormone
US5470834A (en) 1993-10-06 1995-11-28 Florida State University Sulfoximine and suldodiimine matrix metalloproteinase inhibitors
US5403952A (en) 1993-10-08 1995-04-04 Merck & Co., Inc. Substituted cyclic derivatives as novel antidegenerative agents
UA48121C2 (uk) 1993-11-04 2002-08-15 Сінтекс (С.Ш.А.) Інк. Інгібітори матричних металопротеаз і фармацетична композиція на їх основі
GB9323165D0 (en) 1993-11-10 1994-01-05 Chiros Ltd Compounds
EP0822186B1 (en) 1994-01-20 2000-03-15 British Biotech Pharmaceuticals Limited L-tert-leucine-2-pyridylamide
GB9401129D0 (en) 1994-01-21 1994-03-16 British Bio Technology Hydroxamic acid derivatives as metalloproteinase inhibitors
KR970700652A (ko) 1994-01-22 1997-02-12 포올 리틀우드 금속단백질 분해효소 억제제
US5514716A (en) 1994-02-25 1996-05-07 Sterling Winthrop, Inc. Hydroxamic acid and carboxylic acid derivatives, process for their preparation and use thereof
US5665753A (en) 1994-03-03 1997-09-09 Smithkline Beecham Corporation Cytokine inhibiting imidazole substituted hydroxamic acid derivatives
GB9405076D0 (en) 1994-03-16 1994-04-27 Inst Of Ophtalmology A medical use of matrix metalloproteinase inhibitors
DE4411311A1 (de) * 1994-03-31 1995-10-05 Basf Ag Verfahren zur Herstellung von lagerstabilen wäßrigen Lösungen von Vinylamin-Einheiten enthaltenden Polymerisaten
GB9501737D0 (en) 1994-04-25 1995-03-22 Hoffmann La Roche Hydroxamic acid derivatives
WO1995029892A1 (en) 1994-04-28 1995-11-09 The Du Pont Merck Pharmaceutical Company Hydroxamic acid and amino acid derivatives and their use as anti-arthritic agents
JPH07304770A (ja) 1994-05-11 1995-11-21 Kanebo Ltd 新規ベンゾアゼピノン誘導体
ATE181055T1 (de) 1994-05-28 1999-06-15 British Biotech Pharm Succinyl hydroxamsäure-, n-formyl-n-hydroxy- aminocarbonsäure- und succinsäureamid-derivate und ihre verwendung als metalloprotease- inhibitoren
GB9411088D0 (en) 1994-06-03 1994-07-27 Hoffmann La Roche Hydroxylamine derivatives
GB9411598D0 (en) 1994-06-09 1994-08-03 Hoffmann La Roche Hydroxamic acid derivatives
GB9412350D0 (en) 1994-06-20 1994-08-10 Fujisawa Pharmaceutical Co New compound and its preparation
CA2193691A1 (en) 1994-06-22 1995-12-28 Andrew Miller Metalloproteinase inhibitors
GB9416897D0 (en) 1994-08-20 1994-10-12 British Biotech Pharm Metalloproteinase inhibitors
HRP950558A2 (en) 1994-11-15 1997-12-31 Scott M. Wilhelm Substituted 4-biarylbutric or biarylpentanoic acids and derivatives as matrix metalloprotease inhibitors
US5919940A (en) 1995-01-20 1999-07-06 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
US5573438A (en) * 1995-04-25 1996-11-12 D'andrea; Deborah Book including candy as a part of the pages
US5886022A (en) 1995-06-05 1999-03-23 Bayer Corporation Substituted cycloalkanecarboxylic acid derivatives as matrix metalloprotease inhibitors
US6124333A (en) 1995-06-22 2000-09-26 British Biotech Pharmaceuticals Limited Metalloproteinase inhibitors
TW453995B (en) 1995-12-15 2001-09-11 Novartis Ag Certain alpha-substituted arylsulfonamido acetohydroxamic acids
ES2284180T3 (es) * 1996-01-23 2007-11-01 SHIONOGI & CO., LTD. Derivados de aminoacidos sulfonados e inhibidores de metaloproteinasas que contienen los mismos.
AU4159197A (en) 1996-09-04 1998-03-26 Warner-Lambert Company Biphenyl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
IL131042A (en) 1997-02-03 2004-07-25 Pfizer Prod Inc Derivatives of arylsulfonamic acid hydroxyamic acid and medicinal preparations containing them
CA2285405A1 (en) * 1997-03-04 1998-09-11 Monsanto Company Amidoaromatic ring sulfonamide hydroxamic acid compounds
DE19719621A1 (de) * 1997-05-09 1998-11-12 Hoechst Ag Sulfonylaminocarbonsäuren
EP1009737A2 (en) * 1997-07-31 2000-06-21 The Procter & Gamble Company Sulfonylamino substituted hydroxamic acid derivatives as metalloprotease inhibitors
ES2176913T3 (es) * 1997-08-08 2002-12-01 Pfizer Prod Inc Derivados de acidos arilsulfonilaminohidroxamicos.
AU9663798A (en) 1997-10-06 1999-04-27 Warner-Lambert Company Heteroaryl butyric acids and their derivatives as inhibitors of matrix metalloproteinases
TR200002224T2 (tr) 1998-02-04 2000-12-21 Novartis Ag Matris-bozucu metalloproteinasları inhibe eden sülfonilamino türevleri.
PA8469501A1 (es) * 1998-04-10 2000-09-29 Pfizer Prod Inc Hidroxamidas del acido (4-arilsulfonilamino)-tetrahidropiran-4-carboxilico
FR2782080B1 (fr) * 1998-08-10 2001-01-05 Adir Nouveaux derives d'acide hydroxamique, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6677360B2 (en) * 1998-12-16 2004-01-13 Bayer Aktiengesellschaft Biphenyl and biphenyl-analogous compounds as integrin antagonists
US6225311B1 (en) 1999-01-27 2001-05-01 American Cyanamid Company Acetylenic α-amino acid-based sulfonamide hydroxamic acid tace inhibitors
CA2366954A1 (en) 1999-03-03 2000-09-08 The Procter & Gamble Company Dihetero-substituted metalloprotease inhibitors
HN2000000052A (es) 1999-05-28 2001-02-02 Pfizer Prod Inc Hidroxiamidas de acidos 3- (arilsulfonilamino)- tetrahidrofuran-3-carboxilicos.
EP1181286B1 (en) 1999-05-28 2003-11-12 Pfizer Products Inc. 3-(arylsulfonylamino)-tetrahydropyran-3-carboxylic acid hydroxamides
US6696456B1 (en) * 1999-10-14 2004-02-24 The Procter & Gamble Company Beta disubstituted metalloprotease inhibitors
PE20020291A1 (es) * 2000-08-21 2002-04-17 Hoffmann La Roche Profarmacos para ligandos del receptor nmda

Also Published As

Publication number Publication date
US20030139414A1 (en) 2003-07-24
NZ520657A (en) 2004-11-26
MA26884A1 (fr) 2004-12-20
KR20020081465A (ko) 2002-10-26
IL151125A0 (en) 2003-04-10
EP1265864A1 (en) 2002-12-18
PL365444A1 (en) 2005-01-10
US20040127498A1 (en) 2004-07-01
PE20011137A1 (es) 2001-12-04
US6949545B2 (en) 2005-09-27
AR030197A1 (es) 2003-08-13
WO2001070691A1 (en) 2001-09-27
SK12842002A3 (sk) 2003-02-04
MXPA02009311A (es) 2003-03-12
AU2001245891A1 (en) 2001-10-03
CN1425004A (zh) 2003-06-18
ZA200206298B (en) 2003-04-11
RU2245876C2 (ru) 2005-02-10
BR0109328A (pt) 2003-06-10
HUP0300235A2 (hu) 2003-08-28
JP2003528080A (ja) 2003-09-24
RU2002128007A (ru) 2004-02-27
CA2404131A1 (en) 2001-09-27
NO20024520D0 (no) 2002-09-20
CZ20023145A3 (cs) 2003-01-15

Similar Documents

Publication Publication Date Title
NO20024521D0 (no) Heterocyklisk sidekjede-inneholdende metalloproteaseinhibitorer
NO20031853D0 (no) Spiro-pyrimidin-2,4,6-trion metalloproteinase inhibitorer
CY2015053I2 (el) Υδροξαμικα παραγωγα χρησιμα ως αναστολεις δεακετυλασης
DE60002193D1 (de) Metalloprotease inhibitoren
ATE524441T1 (de) Vla-4-inhibitoren
ATE308544T1 (de) N-substituiete heteroaryloxy-aryl-spiro- pyrimidine-2,4,6-trion metalloproteinase inhibitoren
CY2012007I2 (el) Πεπτιδομιμητικοι αναστολεις πρωτεασης
ATE304015T1 (de) Triaryl-oxy-aryl-spiro-pyrimidin-2, 4, 6-trion metalloproteinase inhibitoren
EE200100486A (et) Amiinderivaadid proteaasi inhibiitoritena
NO20024520L (no) Heterocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer
DK1272488T3 (da) Tri-aryl-substitueret ethan-PDE4-inhibitorer
NO20014243D0 (no) Dihetero-substituerte metalloprotease inhibitorer
NO20032807L (no) Substituerte 8-arylkinolin-fosfodiesterase-4-inhibitorer
NO20024518D0 (no) Karbocyklisk sidekjede-inneholdende, N-substituerte metalloproteaseinhibitorer
NO20025786L (no) Protaseinhibitorer
NO20025659L (no) Heterocykliske forbindelser
NO20025005L (no) Proteaseinhibitorer
NO20025281D0 (no) Peptid-deformylase-inhibitorer
NO20023675L (no) Heterocykliske amidderivater
NO20030375L (no) N-substituerte 1-amino-1,1-dialkylkarboksylsyrederivater
NO20025282D0 (no) Peptid-deformylase-inhibitorer
NO20032328L (no) Proteaseinhibitorer
DK1296985T3 (da) Heteropolycykliske inhibitorer

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application